Dr Reddy’s Laboratories Ltd could begin late-stage Indian clinical trials of Russia’s potential coronavirus vaccine in the next few weeks, an executive at the Indian drugmaker said on Tuesday.Indian trials of the Sputnik-V vaccine candidate, being developed by Russia`s sovereign wealth fund, will enroll 1,000-2,000 participants and be conducted at multiple government and private hospitals across the country, Deepak Sapra, CEO for API and pharmaceutical services at Dr. Reddy`s, told Reuters.”We want to get to the first step – which is the commencement of the clinical trials by getting the necessary approvals from the Indian regulators – within the next few weeks,” Sapra said.The trials are part of a deal between the Russian Direct Investment Fund (RDIF) and Dr Reddy`s, in which the Indian firm will conduct Phase III studies in India, pursue local regulatory approvals and,…